Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus for PIK3CA-Related Overgrowth Spectrum (PROS)
NCT02428296Phase 2Completed
- Sponsor
- National Human Genome Research Institute
- Start
- Apr 2015
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sirolimus in PIK3CA-related overgrowth spectrum (PROS), sponsored by National Human Genome Research Institute. Started Apr 2015; status: completed.
02
Drugs
sirolimus
03
Conditions
PIK3CA-related overgrowth spectrum (PROS)
Beyond the preview
Go deeper on NCT02428296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02428296.